Giant Cell Arteritis and Polymyalgia Rheumatica : Treatment Approaches and New Targets
Copyright © 2023 Elsevier Inc. All rights reserved..
Prolonged glucocorticoid tapers have been the standard of care for giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), but recent advancements have improved outcomes for patients with GCA while reducing glucocorticoid-related toxicities. Many patients with GCA and PMR still experience persistent or relapsing disease, and cumulative exposure to glucocorticoids for both diseases remains high. The objective of this review is to define current treatment approaches as well as new therapeutic targets and strategies. Studies investigating inhibition of cytokine pathways, including interleukin-6, interleukin-17, interleukin-23, granulocyte-macrophage colony-stimulating factor, Janus kinase-signal transduction and activator of transcription, and others, will be reviewed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Rheumatic diseases clinics of North America - 49(2023), 3 vom: 18. Aug., Seite 505-521 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nepal, Desh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Abatacept |
|---|
| Anmerkungen: |
Date Completed 20.06.2023 Date Revised 20.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rdc.2023.03.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358332826 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358332826 | ||
| 003 | DE-627 | ||
| 005 | 20231226074522.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.rdc.2023.03.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358332826 | ||
| 035 | |a (NLM)37331730 | ||
| 035 | |a (PII)S0889-857X(23)00036-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nepal, Desh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Giant Cell Arteritis and Polymyalgia Rheumatica |b Treatment Approaches and New Targets |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.06.2023 | ||
| 500 | |a Date Revised 20.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Prolonged glucocorticoid tapers have been the standard of care for giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), but recent advancements have improved outcomes for patients with GCA while reducing glucocorticoid-related toxicities. Many patients with GCA and PMR still experience persistent or relapsing disease, and cumulative exposure to glucocorticoids for both diseases remains high. The objective of this review is to define current treatment approaches as well as new therapeutic targets and strategies. Studies investigating inhibition of cytokine pathways, including interleukin-6, interleukin-17, interleukin-23, granulocyte-macrophage colony-stimulating factor, Janus kinase-signal transduction and activator of transcription, and others, will be reviewed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Abatacept | |
| 650 | 4 | |a Giant cell arteritis | |
| 650 | 4 | |a Glucocorticoids | |
| 650 | 4 | |a Guselkumab | |
| 650 | 4 | |a Mavrilimumab | |
| 650 | 4 | |a Polymyalgia rheumatica | |
| 650 | 4 | |a Secukinumab | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 700 | 1 | |a Putman, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Unizony, Sebastian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatic diseases clinics of North America |d 1988 |g 49(2023), 3 vom: 18. Aug., Seite 505-521 |w (DE-627)NLM012610534 |x 1558-3163 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2023 |g number:3 |g day:18 |g month:08 |g pages:505-521 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rdc.2023.03.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2023 |e 3 |b 18 |c 08 |h 505-521 | ||